ArticleAmerican journal of nephrology2022
Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes.
Article in American journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Pooled it
- Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026Review
- Urine as a source of biomarkers and biological knowledge in chronic kidney disease.Nature reviews. Nephrology · 2026Review
- Inflammation: The Pathological Axis of Cisplatin-Induced Renal Injury.Journal of inflammation research · 2026Review
- Establishment of a YKL-40 time-resolved Immunoassay and Application in Diabetic Kidney Disease.Journal of fluorescence · 2025Article
- A Comprehensive Framework for Kidney Function Assessment: Summary of the National Institute of Diabetes and Digestive and Kidney Diseases Reimagining Kidney Function Assessment Workshop.Kidney international reports · 2025Article
- Defining Kidney Health Dimensions and Their Associations with Adverse Outcomes in Persons with Diabetes and CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Surrogate endpoints in diabetic kidney disease: current perspectives and future directions.Frontiers in endocrinology · 2025Review
- Inflammatory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Urine Epidermal Growth Factor and Kidney Function Decline in Middle-Aged Adults.Kidney medicine · 2024Article
- Urinary non-albumin protein-creatinine ratio is an independent predictor of mortality in patients with type 2 diabetes: a retrospective cohort study.Scientific reports · 2024Article
- Biomarkers of chronic kidney disease in older individuals: navigating complexity in diagnosis.Frontiers in medicine · 2024Review
- Integrated Analysis of Ferroptosis and Immunity-Related Genes Associated with Diabetic Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Role of MCP-1 as an inflammatory biomarker in nephropathy.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
introductionDiabetes is a leading cause of end-stage kidney disease (ESKD). Biomarkers of tubular health may prognosticate chronic kidney disease (CKD) progression beyond estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR).
methodsWe examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR ≥30 mL/min/1.73 m2 if randomization eGFR ≥60 or ≥50% if randomization eGFR <60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. Covariates included age, sex, race, BMI, systolic BP, HbA1c, treatment arm, eGFR, and UACR. In a subset of participants with 12-month samples (n = 712), we evaluated associations of KIM-1, MCP-1, and YKL-40 change (from baseline to 12 months) with eGFR decline (from 12 months onward).
resultsAt baseline, mean age was 65 years, mean eGFR was 56 mL/min/1.73 m2, and median UACR was 840 mg/g. Over a median of 2.2 years, 13% experienced kidney function decline and 9% died. In fully adjusted models, the highest versus lowest quartiles of MCP-1 and YKL-40 were associated with 2.18- and 1.76-fold higher risks of kidney function decline, respectively. One-year changes in KIM-1, MCP-1, and YKL-40 were not associated with subsequent eGFR decline. Higher baseline levels of NGAL, IL-18, MCP-1, and YKL-40 levels (per 2-fold higher) were independently associated with 10-40% higher risk of mortality.
conclusionAmong Veterans with diabetes and CKD, urinary biomarkers of tubular health were associated with kidney function decline and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.